When Stiller was 46, he went to see his doctor, Bernard Kruger, MD, for a regular check up. Kruger talked to him about his age-based risk of prostate cancer and recommended a blood test to get a baseline reading of the actor’s prostate-specific antigen (PSA) levels. When the results came back, his numbers were high, but not necessarily troubling. Kruger opted for a “wait and see” approach, retesting him every six months over the next two years.
During that time, Stiller’s PSA numbers steadily rose—a subtle change indicating a problem that would’ve been undetectable without that initial screening. Finally reaching levels that his doctor found alarming, the actor underwent additional testing, including a digital prostate exam, MRI, and eventually a biopsy. These tests ultimately confirmed a diagnosis of prostate cancer.
“If I hadn’t gotten the test… right now I still wouldn’t have known,” he told radio host Howard Stern during a 2016 interview.
The Goodbody Health Group Inc. is listed on the Canadian Securities Exchange (CSE), the Aquis Stock Exchange – Growth Market (AQSE) Apex segment, OTC Pink, and Frankfurt Stock Exchange (FSE), providing current and prospective shareholders with multiple platforms in which to buy and sell Goodbody Health Group Inc. stock under the EPIC codes: CSE: GDBY / AQSE: GDBY / FRA: 484 / OTC: GDBYF).